Ovarian cancer ranks first in mortality among malignant tumors of the female reproductive system. According to data from the International Agency for Research on Cancer (IARC) of the World Health Organization, advanced metastatic cases account for more than 70% of all ovarian cancer cases. Highly metastatic ovarian cancer is characterized by occult onset, a high tendency for extensive peritoneal implant metastasis, and persistently high recurrence rates, with a 5-year survival rate of less than 20% in the advanced stage. For a long time, it has been plagued by multiple clinical challenges, including unclear metastatic mechanisms, platinum chemotherapy resistance rates exceeding 60%, limited populations benefiting from targeted drugs, and the lack of exclusive treatment regimens for "immunologically cold tumors", imposing an enormous disease burden.

I. Breakthroughs in Basic Scientific Research: Targeting the Dual Core Pain Points of Metastatic Mechanisms and Treatment Resistance

(I) Landmark New Discovery: Deciphering the Core Code of Peritoneal Metastasis in Highly Metastatic Ovarian Cancer

Extensive peritoneal implant metastasis is the most typical feature of highly metastatic ovarian cancer and also the key cause of treatment failure and extremely poor prognosis in patients. Previous studies only identified relevant clinical phenomena but failed to clarify the core molecular mechanisms underlying the directional metastasis and colonization of tumor cells.

Recently, the research team led by Professor Yin Gang from the Xiangya Hospital of Central South University published a landmark study in Molecular Cancer (IF=33.9), revealing a novel metastatic mechanism of highly metastatic ovarian cancer: highly metastatic cancer cells secrete exosomal LINC01123, which encodes the 59-amino acid micropeptide YG-6. YG-6 activates the focal adhesion pathway by binding to ACTC1, promotes the migration and adhesion of low-metastatic cancer cells, and directly drives peritoneal implant metastasis. YG-6 can serve as a prognostic marker for ovarian cancer, and the related technology has obtained a national invention patent. In the same period, a research team from Sun Yat-sen University confirmed that the polyamine metabolic enzyme SAT1 is a key target for pelvic and peritoneal metastasis, and targeted inhibition of this target can effectively block metastasis.

Reference 1

(II) Core Breakthroughs in Targeted Therapy: Overcoming Chemotherapy/Targeted Drug Resistance and Realizing Precise Treatment of Metastatic Lesions

More than 80% of highly metastatic ovarian cancer cases are diagnosed at the advanced stage, with chemotherapy as the foundational treatment, yet the platinum resistance rate is as high as over 60%. Although PARP inhibitors have brought clinical benefits to patients with BRCA mutations, secondary resistance and the lack of available drugs for patients with negative germline mutations remain core challenges. From 2025 to 2026, targeted therapy has achieved multiple innovations in the breakthrough of "undruggable" targets, deciphering drug resistance mechanisms, and precise intervention of metastatic lesions, stepping into a new era of "combined precise attack" from "single-target therapy".

Individualized Niraparib Regimen Prolongs Survival in Patients with Platinum-Sensitive Recurrent Ovarian Cancer

The final overall survival (OS) analysis of the NORA Phase III study, led by the research team of Professor Wu Xiaohua from Fudan University Shanghai Cancer Center and published in EClinicalMedicine, confirmed that maintenance therapy with niraparib at an individualized starting dose can significantly prolong the overall survival of patients with platinum-sensitive recurrent ovarian cancer, balancing efficacy and safety. This provides high-level evidence-based evidence for clinical individualized maintenance therapy and further optimizes the diagnosis and treatment strategies for patients with drug resistance/recurrence.

Reference 2

2. Targeted Immunotherapy Combination Regimen Breaks Through the Treatment Bottleneck of Recurrent and Refractory Ovarian Cancer

A Phase I clinical study led by the University of Pittsburgh confirmed that the targeted immunotherapeutic agent Lymphir (Denileukin diftitox) combined with the PD-1 inhibitor pembrolizumab exhibited positive clinical activity and manageable safety in patients with recurrent or refractory ovarian cancer. This regimen improves the tumor immunosuppressive microenvironment by transiently depleting regulatory T cells and enhances the anti-tumor effect of PD-1 inhibitors, bringing new treatment hope to patients who have failed multiple lines of standard therapy. The complete efficacy and safety data will be presented at international oncology conferences in 2026, laying a solid foundation for subsequent Phase II studies.

II. 2026 FDA Key Approval Dynamics: A Number of New Drugs Sprint for Marketing, Covering All Drug-Resistant/Metastatic Subtypes

III. Enterprise Pipeline Layout: Marketed Drugs Solidify Core Foundations, Clinical-Stage Agents Target Key Metastatic and Resistant Targets​

(I) Marketed Drugs: Reshaping Treatment Standards for Highly Metastatic Ovarian Cancer

(II) Clinical-Stage New Drugs: From Target Breakthroughs to Combined Tackling, Covering All Scenarios of Metastasis/Drug Resistance

Novel ADC Drugs: Precisely Targeting Tumor Cells in Metastatic LesionsRecurrent ovarian cancer cases after platinum resistance and failure of PARP inhibitor therapy have long been a core clinical pain point. B7-H4 is highly expressed in ovarian cancer and is closely associated with tumor progression and immune escape, emerging as a popular novel target for targeted therapy of gynecological tumors. Mocertatug rezetecan (HS-20089), a next-generation B7-H4-targeted ADC independently developed by Hansen Pharmaceutical, features a high-affinity fully human antibody, a cleavable linker, and a potent payload design. It exhibits excellent anti-tumor activity and a bystander effect, effectively addressing the challenge of tumor heterogeneity.

2.Combined Targeted Regimens: Deciphering the Dilemma of Multidrug Resistance

PARP inhibitor + ATR inhibitor (AZD6738): Developed by AstraZeneca, targeting BRCA wild-type, platinum-resistant ovarian cancer. It achieves synergistic inhibition of dual pathways and breaks through the limitations of single-target drug resistance.

PI3Kα inhibitor + mTOR inhibitor: Developed by Novartis, targeting PIK3CA-mutated highly metastatic ovarian cancer. It conducts combined intervention of abnormal signaling pathways and effectively overcomes the dual drug resistance to chemotherapy and targeted drugs.

References

1. Lei H, Zhou Z, Li C, et al. Micropeptide YG-6 encoded by exosomal LINC01123 derived from highly migratory ovarian cancer cells promotes tumor progression. Mol Cancer. Published online March 5, 2026. doi:10.1186/s12943-026-02621-w

2. Wu X, Zhu J, Yin R, et al. Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial. EClinicalMedicine. 2024;72:102629. Published 2024 May 7. doi:10.1016/j.eclinm.2024.102629